Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Azacitidine

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Polutta A, et al. Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial. Blood 142 (Suppl. 1): 1521, Nov 2023. Available from: URL: https://dx.doi.org/10.1182/blood-2023-180820 [abstract] Polutta A, et al. Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial. Blood 142 (Suppl. 1): 1521, Nov 2023. Available from: URL: https://dx.doi.org/10.1182/blood-2023-180820 [abstract]
Metadaten
Titel
Azacitidine
Lack of efficacy
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53939-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Antineoplastics

Case report

Blinatumomab

Case report

Olaparib